Abstract 18325: Pentraxin3 is Associated with Markers of Endothelial Cell Injury Hypercoagulable State and Severity of Peripheral Arterial Disease in Diabetic Subjects
Pentraxin3 (PTX3) was reported to be expressed in atherosclerotic plaques and high levels were seen in patients with atherosclerosis, however, its role in atherosclerosis needs to be further elucidated. In the present study we measured PTX3 levels in diabetic patients with peripheral atherosclerotic diseases (PAD) and investigated its relation to markers of endothelial dysfunction, severity of PAD using ABI, and platelet function. Data was collected from 118 patients and 20 control subjects, at KKUH. Fasting blood samples were used for measuring, blood sugar, triglesrides, ICAM-1, VCAM-1, PTX3, P-selectin, and fibrinogen. Ankle brachial index (ABI) was measured for all subjects. PTX3 was significantly elevated in patients with PAD compared to control healthy subjects. Markers of endothelial dysfunction (ICAM-1, VCAM-1 and P-Selectin) as well as fibrinogen were higher in patients with PAD compared to controls. These parameters correlated positively with PTX3 suggesting strong association of PTX3 with disease process, however, doesn't provide a causal link. Using multiple regression analysis with PTX3 as a dependent factor and other variables as independent, showed that fibrinogen followed by VCAM-1 is the most determinant factors influencing PTX3. An indirect association of PTX3 was found, with severity of peripheral vascular disease measured by ABI. As PAD is associated with hypercoagulable state, we investigated effect of PTX3, in vitro, on platelet aggregation, by incubating whole blood from healthy donors with PTX3 at different conc. A significant inhibition of platelet aggregation was seen at a conc of PTX3 of 200-400 ng/ml. This inhibition was ameliorated as concentration was increasing. These results might suggest PTX3 as a counter-regulatory molecule rather than inducer in atherosclerosis and its complications. Further investigations are required to study effect of PTX3 on platelet function and vascular smooth muscle cells.
- © 2011 by American Heart Association, Inc.